SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

A decent increase of about 25.67% in the sales to Rs. 3338.30 millions was observed for the quarter ended September 2023. The sales figure stood at Rs. 2656.38 millions during the year-ago period.The Net Loss for the quarter ended September 2023 is Rs. -308.10 millions as compared to Net Loss of Rs. -754.63 millions of corresponding quarter ended September 2022 Operating profit Margin for the quarter ended September 2023 improved to 2.74% as compared to -203.51% of corresponding quarter ended September 2022


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202309 202209 % Var 202309 202209 % Var 202303 202203 % Var
Sales 3338.30 2656.38 25.67 6804.97 5104.19 33.32 10724.32 9429.27 13.73
Other Income 75.81 107.80 -29.68 134.07 226.25 -40.74 418.48 420.68 -0.52
PBIDT 2.74 -203.51 -101.35 144.09 -193.93 -174.30 -510.65 -14.86 3336.41
Interest 38.25 30.21 26.61 63.00 46.88 34.39 93.80 20.74 352.27
PBDT -35.51 -283.94 -87.49 81.09 -291.03 -127.86 -1731.09 -35.60 4762.61
Depreciation 272.59 264.57 3.03 546.22 490.27 11.41 1059.79 831.88 27.40
PBT -308.10 -548.51 -43.83 -465.13 -781.30 -40.47 -2790.88 -867.48 221.72
TAX 0.00 206.12 0.00 0.00 206.12 0.00 206.12 -313.18 -165.82
Deferred Tax 0.00 206.12 0.00 0.00 206.12 0.00 206.12 -315.55 -165.32
PAT -308.10 -754.63 -59.17 -465.13 -987.42 -52.89 -2997.00 -554.30 440.68
Equity 140.81 140.81 0.00 140.81 140.81 0.00 140.81 140.81 0.00
PBIDTM(%) 0.08 -7.66 -101.07 2.12 -3.80 -155.73 -4.76 -0.16 2921.32

Unichem Lab Share Price

350.85 4.85 (1.40%)
17-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1675.20
Dr. Reddys Lab 1235.40
Cipla 1238.30
Zydus Lifesciences 942.55
Lupin 2324.25
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×